
	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Numerator:
Loss from continuing operations	$	(36,373)	$	(201,018)	$	(26,979)	$	(204,395)
Less: Net (loss) income attributable to noncontrolling interests	(4)		(168)		(112)		45




Net loss from continuing operations available to common stockholders, basic and diluted	$	(36,369)	$	(200,850)	$	(26,867)	$	(204,440)
Denominator:
Basic weighted-average common shares outstanding	399,351		390,905		397,264		388,601



Diluted weighted-average common shares outstanding	399,351		390,905		397,264		388,601
Loss per share from continuing operations:
Basic	$	(0.09)	$	(0.51)	$	(0.07)	$	(0.53)
Diluted	$	(0.09)	$	(0.51)	$	(0.07)	$	(0.53)

Basic earnings per share is computed by dividing net income from continuing operations available to common stockholders by the weighted-average number of common shares outstanding during each period. Diluted earnings per share is computed by dividing net income from continuing operations available to common stockholders by the weighted-average number of common shares outstanding plus the effect of all dilutive common stock equivalents during each period. The diluted weighted-average common shares outstanding calculation excludes 4 million and 2 million of dilutive restricted stock awards for the three and six months ended June 30, 2026, respectively, and 3 million and 8 million of dilutive stock options and restricted stock awards for the three and six months ended June 30, 2025, respectively, as their effect would be anti-dilutive given the net loss incurred in the period. The calculation of diluted weighted-average shares excludes the impact of 5 million and 12 million of anti-dilutive common stock equivalents for the three and six months ended June 30, 2026, respectively, and 2 million of anti-dilutive common stock equivalents for the three months ended June 30, 2025. The impact of anti-dilutive common stock equivalents for the six months ended June 30, 2025 is not material.

We have used the if-converted method for calculating any potential dilutive effect of the Exchangeable Notes on our diluted net income per share. Under the if-converted method, the 2025 Exchangeable Notes and 2026 Exchangeable Notes are assumed to be converted at the beginning of each period, the 2031 Exchangeable Notes are assumed to be converted at the issuance date of May 18, 2026 and the resulting common shares are included in the denominator of the diluted earnings per share calculation for the entire period being presented and interest expense, net of tax, recorded in connection with the Exchangeable Notes is added back to the numerator, only in the periods in which such effect is dilutive. The approximately 55 million and 44 million resulting common shares related to the outstanding Exchangeable Notes for the three and six months ended June 30, 2026, respectively, and approximately 37 million and 47 million resulting common shares related to the then-outstanding Exchangeable Notes for the three and six months ended June 30, 2025, respectively, are not included in the dilutive weighted-average common shares outstanding calculation as their effect would be anti-dilutive given the net loss incurred in the periods.